147 related articles for article (PubMed ID: 22215120)
1. Anti-cyclic citrullinated peptide antibodies in scleroderma patients.
Polimeni M; Feniman D; Skare TS; Nisihara RM
Clin Rheumatol; 2012 May; 31(5):877-80. PubMed ID: 22215120
[TBL] [Abstract][Full Text] [Related]
2. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis.
Ingegnoli F; Galbiati V; Zeni S; Meani L; Zahalkova L; Lubatti C; Soldi A; Paresce E; Murgo A; Crapanzano C; Fantini F
Clin Rheumatol; 2007 Apr; 26(4):510-4. PubMed ID: 16670827
[TBL] [Abstract][Full Text] [Related]
3. Anti-agalactosyl IgG antibodies in Thai patients with rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis.
Louthrenoo W; Kasitanon N; Wichainun R; Wangkaew S; Sukitawut W; Kuwata S; Takeuchi F
Clin Rheumatol; 2010 Mar; 29(3):241-6. PubMed ID: 20091076
[TBL] [Abstract][Full Text] [Related]
4. Anti-CCP antibodies and rheumatoid factor in systemic sclerosis: Prevalence and relationships with joint manifestations.
Wielosz E; Majdan M; Dryglewska M; Zwolak R
Adv Clin Exp Med; 2018 Sep; 27(9):1253-1257. PubMed ID: 30024658
[TBL] [Abstract][Full Text] [Related]
5. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
[TBL] [Abstract][Full Text] [Related]
6. Clinical and serological hallmarks of systemic sclerosis overlap syndromes.
Pakozdi A; Nihtyanova S; Moinzadeh P; Ong VH; Black CM; Denton CP
J Rheumatol; 2011 Nov; 38(11):2406-9. PubMed ID: 21844148
[TBL] [Abstract][Full Text] [Related]
7. [Prevalence of anti-CCP antibodies in systemic sclerosis].
Marrone M; Chialà A; Tampoia M; Iannone F; Raho L; Covelli M; Grattagliano V; Pansini N; Lapadula G
Reumatismo; 2007; 59(1):20-4. PubMed ID: 17435838
[TBL] [Abstract][Full Text] [Related]
8. Anti-cyclic citrullinated peptide antibody in systemic sclerosis.
Morita Y; Muro Y; Sugiura K; Tomita Y
Clin Exp Rheumatol; 2008; 26(4):542-7. PubMed ID: 18799082
[TBL] [Abstract][Full Text] [Related]
9. Significance of combined anti-CCP antibodies and rheumatoid factor in a New Zealand cohort of patients with systemic sclerosis.
Kamalaksha S; White DHN; Solanki KK
Int J Rheum Dis; 2018 Jul; 21(7):1430-1435. PubMed ID: 29968328
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis.
Ha JW; Hong YJ; Cha HJ; Moon JD; Pyo JY; Lee SW; Park YB; Park CH; Song JJ
Sci Rep; 2022 Nov; 12(1):19253. PubMed ID: 36357514
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis.
Santiago M; Baron M; Miyachi K; Fritzler MJ; Abu-Hakima M; Leclercq S; Bell M; Hudson M; Mathieu JP; Taillefer S; Jones N; Docherty P; Khraishi M; Markland J; Pope J; Robinson D; Smith D; Sutton E
Clin Rheumatol; 2008 Jan; 27(1):77-83. PubMed ID: 17570008
[TBL] [Abstract][Full Text] [Related]
12. Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients.
Skare TL; Nisihara R; Barbosa BB; da Luz A; Utiyama S; Picceli V
Clin Rheumatol; 2013 Jul; 32(7):1065-70. PubMed ID: 23412637
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis.
Ueda-Hayakawa I; Hasegawa M; Kumada S; Tanaka C; Komura K; Hamaguchi Y; Takehara K; Fujimoto M
Rheumatology (Oxford); 2010 Nov; 49(11):2135-9. PubMed ID: 20663814
[TBL] [Abstract][Full Text] [Related]
14. [Detecting anti-cyclic citrullinated peptide antibody in patients with connective tissue diseases].
Yin G; Cen XM; Yang M; Xie QB
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):374-7. PubMed ID: 21827002
[TBL] [Abstract][Full Text] [Related]
15. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients.
Payet J; Goulvestre C; Bialé L; Avouac J; Wipff J; Job-Deslandre C; Batteux F; Dougados M; Kahan A; Allanore Y
J Rheumatol; 2014 Dec; 41(12):2395-402. PubMed ID: 25274898
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of antiphospholipid antibodies in systemic sclerosis and association with primitive pulmonary arterial hypertension and endothelial injury.
Assous N; Allanore Y; Batteux F; Meune C; Toulon P; Weill B; Kahan A
Clin Exp Rheumatol; 2005; 23(2):199-204. PubMed ID: 15895890
[TBL] [Abstract][Full Text] [Related]
17. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of 405 Japanese patients with systemic sclerosis.
Hashimoto A; Endo H; Kondo H; Hirohata S
Mod Rheumatol; 2012 Apr; 22(2):272-9. PubMed ID: 21874591
[TBL] [Abstract][Full Text] [Related]
19. Overlap between systemic sclerosis and rheumatoid arthritis: a distinct clinical entity?
Horimoto AM; da Costa IP
Rev Bras Reumatol Engl Ed; 2016; 56(4):287-98. PubMed ID: 27476621
[TBL] [Abstract][Full Text] [Related]
20. What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus?
Zhao Y; Li J; Li XX; Li C; Li L; Li ZG
Joint Bone Spine; 2009 Oct; 76(5):501-7. PubMed ID: 19289297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
